Novel potent pyridoxine-based inhibitors of AChE and BChE, structural analogs of pyridostigmine, with improved in vivo safety profile

被引:21
作者
Strelnik, Alexey D. [1 ]
Petukhov, Alexey S. [1 ]
Zueva, Irina V. [1 ,2 ]
Zobov, Vladimir V. [1 ,2 ]
Petrov, Konstantin A. [1 ,2 ]
Nikolsky, Evgeny E. [1 ,4 ]
Balakin, Konstantin V. [1 ,3 ]
Bachurin, Sergey O. [3 ]
Shtyrlin, Yurii G. [1 ]
机构
[1] Kazan Volga Reg Fed Univ, Kremlyovskaya 18, Kazan 420008, Russia
[2] Russian Acad Sci, KazSC, AE Arbuzov Inst Organ & Phys Chem, Arbuzova 8, Kazan 420088, Russia
[3] Russian Acad Sci, Inst Physiol Act Cpds, Severnyi Pr 1, Chernogolovka 142432, Moscow Reg, Russia
[4] Kazan Inst Biochem & Biophys, Lobachevsky St 2-31, Kazan 420111, Russia
关键词
Substituted pyridoxines; Pyridostigmine analogs; Neuromuscular disorders treatment; Acetylcholinesterase (AChE) inhibitors; Carbamate cholinesterase inhibitors; ANTIBACTERIAL ACTIVITY; PHOSPHONIUM SALTS; ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; RECEPTORS;
D O I
10.1016/j.bmcl.2016.06.070
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report a novel class of carbamate-type ChE inhibitors, structural analogs of pyridostigmine. A small library of congeneric pyridoxine-based compounds was designed, synthesized and evaluated for AChE and BChE enzymes inhibition in vitro. The most active compounds have potent enzyme inhibiting activity with IC50 values in the range of 0.46-2.1 mu M ( for AChE) and 0.59-8.1 mu M (for BChE), with moderate selectivity for AChE comparable with that of pyridostigmine and neostigmine. Acute toxicity studies using mice models demonstrated excellent safety profile of the obtained compounds with LD50 in the range of 22-326 mg/kg, while pyridostigmine and neostigmine are much more toxic (LD50 3.3 and 0.51 mg/kg, respectively). The obtained results pave the way to design of novel potent and safe cholinesterase inhibitors for symptomatic treatment of neuromuscular disorders. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4092 / 4094
页数:3
相关论文
共 21 条
  • [1] [Anonymous], [No title captured]
  • [2] Ayupov RK, 2015, RES J PHARM BIOL CHE, V6, P1717
  • [3] Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase
    Darvesh, Sultan
    Darvesh, Katherine V.
    McDonald, Robert S.
    Mataija, Diane
    Walsh, Ryan
    Mothana, Sam
    Lockridge, Oksana
    Martin, Earl
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (14) : 4200 - 4212
  • [4] A NEW AND RAPID COLORIMETRIC DETERMINATION OF ACETYLCHOLINESTERASE ACTIVITY
    ELLMAN, GL
    COURTNEY, KD
    ANDRES, V
    FEATHERSTONE, RM
    [J]. BIOCHEMICAL PHARMACOLOGY, 1961, 7 (02) : 88 - &
  • [5] Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment (vol 14, pg 420, 2015)
    Engel, A. G.
    Shen, X-M
    Selcen, D.
    Sine, S. M.
    [J]. LANCET NEUROLOGY, 2015, 14 (05) : 461 - 461
  • [6] Myasthenia gravis - autoantibody characteristics and their implications for therapy
    Gilhus, Nils Erik
    Skeie, Geir Olve
    Romi, Fredrik
    Lazaridis, Konstantinos
    Zisimopoulou, Paraskevi
    Tzartos, Socrates
    [J]. NATURE REVIEWS NEUROLOGY, 2016, 12 (05) : 259 - U91
  • [7] Acetylcholinesterase inhibitors and Gulf War illnesses
    Golomb, Beatrice Alexandra
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (11) : 4295 - 4300
  • [8] Congenital myasthenic syndromes: an update
    Hantai, Daniel
    Nicole, Sophie
    Eymard, Bruno
    [J]. CURRENT OPINION IN NEUROLOGY, 2013, 26 (05) : 561 - 568
  • [9] Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment
    Kharlamova, Alexandra D.
    Lushchekina, Sofya V.
    Petrov, Konstantin A.
    Kots, Ekaterina D.
    Nachon, Florian
    Villard-Wandhammer, Marielle
    Zueva, Irina V.
    Krejci, Eric
    Reznik, Vladimir S.
    Zobov, Vladimir V.
    Nikolsky, Evgeny E.
    Masson, Patrick
    [J]. BIOCHEMICAL JOURNAL, 2016, 473 : 1225 - 1236
  • [10] Treatment of Myasthenia Gravis
    Kumar, Vikas
    Kaminski, Henry J.
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (01) : 89 - 96